VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Withdrawn

• Conditions: Preterm Infants Developing Normally; Preterm Infants With White Matter Damage

• Registration Number: NCT00564161
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Detailed Description

Not available

Study Timeline

• Status Verified: 2007-11
• Study First Submitted: 2007-11-25
• Study First Submitted QC: 2007-11-26
• Study First Posted: 2007-11-27
• Study Start: 2008-01
• Study Completion: 2009-01
• Last Update Submitted: 2016-09-01
• Last Update Posted: 2016-09-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Preterm infants undergoing lumbar puncture.

Exclusion Criteria

• Preterm with IVH or known infection or meningitis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified